A multi-center phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer

Shinichi Toyooka,Norihito Okumura,Hiroshige Nakamura,Masao Nakata,Motohiro Yamashita,Hirohito Tada,Shinsuke Kajiwara,Naoki Watanabe,Morihito Okada,Keitaro Matsuo,Motoi Aoe,Katsuyuki Hotta,Junichi Sakamoto,Shinichiro Miyoshi,Hiroshi Date

A multi-center phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer

2016

Shinichi Toyooka
Norihito Okumura
Hiroshige Nakamura
Masao Nakata
Motohiro Yamashita
Hirohito Tada
Shinsuke Kajiwara
Naoki Watanabe
Morihito Okada
Keitaro Matsuo
Motoi Aoe
Katsuyuki Hotta
Junichi Sakamoto
Shinichiro Miyoshi
Hiroshi Date

8521Background: Previous studies have reported that adjuvant chemotherapy provides a survival benefit in patients with resected non-small cell lung cancer (NSCLC). In Japan, uracil-tegafur (UFT) ha...

Keywords:

Carboplatin/paclitaxel
Adjuvant
Cell
Uracil
Pathology
Lung cancer
Oncology
Tegafur
Internal medicine
Medicine
Chemotherapy
adjuvant chemotherapy
survival benefit
in patient
non small cell
uracil tegafur

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations